Low incidences of human immunodeficiency virus and hepatitis C virus infection and declining risk behaviors in a cohort of injection drug users in Chennai, India

American Journal of Epidemiology

Volumn 172, Issue 11, 2010, Pages 1259-1267

  Solomon, Sunil Suhas ^a,b   Celentano, David D ^b   Srikrishnan, Aylur K ^a   Vasudevan, Canjeevaram K ^a   Murugavel, Kalilapuri G ^a   Iqbal, Syed H ^a   Anand, Santhanam ^a   Kumar, Muniratnam Suresh ^a   Latkin, Carl ^b   Solomon, Suniti ^a   Mehta, Shruti H ^b  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cohort studies; hepacivirus; HIV; India; risk taking; substance abuse, intravenous

Indexed keywords

ANTIBODY; COHORT ANALYSIS; DISEASE PREVALENCE; DRUG; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; COUNSELING; FEMALE; HEALTH BEHAVIOR; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; INTRAVENOUS DRUG ABUSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; RISK REDUCTION; SELF REPORT;

ADULT; ALCOHOL DRINKING; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DRUG USERS; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; LONGITUDINAL STUDIES; MALE; POPULATION SURVEILLANCE; QUESTIONNAIRES; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

CHENNAI; INDIA; TAMIL NADU;

CALYPTE; HEPACIVIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649655487     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq288     Document Type: Article

References (36)

1. National AIDS Control Organisation, Ministry of Health and Family Welfare. HIV Sentinel Surveillance and HIV Estimation in India 2007-A Technical Brief. New Delhi, India: Ministry of Health and Family Welfare; 2008. (http://www. nacoonline.org/upload/Publication/M&E%20Surveillance, %20Research/HIV%20Sentinel%20Surveillance%20 and%20HIV%20Estimation%202007- A%20Technical%20 Brief.pdf). (Accessed November 10, 2009).
2. National AIDS Control Organisation, Ministry of Health and Family Welfare. HIV Sentinel Surveillance Country Report 2006. New Delhi, India: Ministry of Health and Family Welfare; 2007. http://nacoonline.org/upload/ NACO%20PDF/HIV%20Sentinel%20Surveillance%202006-India%20 Country%20Report.pdf). (Accessed September 17, 2010).
3. Arora P, Kumar R, Bhattacharya M, et al. Trends in HIV incidence in India from 2000 to 2007. Lancet. 2008;372(9635): 289-290.
4. Kumar R, Jha P, Arora P, et al. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet. 2006;367(9517):1164-1172.
5. Aceijas C, Friedman SR, Cooper HL, et al. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect. 2006;82(suppl 3):iii10-iii17.
6. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651): 1733-1745.
7. Sarkar S, Das N, Panda S, et al. Rapid spread of HIV among injecting drug users in north-eastern states of India. Bull Narc. 1993;45(1):91-105.
8. Solomon SS, Srikrishnan AK, Mehta SH, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008;49(3): 327-332.
9. Solomon SS, Desai M, Srikrishnan AK, et al. The profile of injection drug users in Chennai, India: identification of risk behaviours and implications for interventions. Subst Use Misuse. 2010;45(3):354-367.
10. Solomon SS, Hawcroft CS, Narasimhan P, et al. Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res. 2008;127(5):447-452.
11. Solomon SS, Celentano DD, Srikrishnan AK, et al. Mortality among injection drug users in Chennai, India (2005-2008). AIDS. 2009;23(8):997-1004.
12. Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses. 2002;18(4): 295-307.
13. Karita E, Price M, Hunter E, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS. 2007;21(4):403-408.
14. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280(1): 42-48.
15. Dobbs T, Kennedy S, Pau CP, et al. Performance characteristics of the immunoglobulin G-capture BED-enzyme immu-noassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol. 2004;42(6): 2623-2628.
16. Kumarasamy N, Solomon S, Flanigan TP, et al. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis. 2003;36(1):79-85.
17. Ruan Y, Qin G, Yin L, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2007;21(suppl 8): S39-S46.
18. Kozlov AP, Shaboltas AV, Toussova OV, et al. HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia. AIDS. 2006;20(6):901-906.
19. Zhang Y, Shan H, Trizzino J, et al. HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int J Infect Dis. 2007;11(4):318-323.
20. Vanichseni S, Kitayaporn D, Mastro TD, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS. 2001;15(3): 397-405.
21. McDougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses. 2006;22(10):945-952.
22. Lakshmi V, Sudha T, Dandona R, et al. Application of human immunodeficiency virus type 1 BED enzyme immunoassay on dried blood spots in India. J Med Microbiol. 2009;58(3): 312-317.
23. Nelson KE, Vlahov D, Solomon L, et al. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, MD. Arch Intern Med. 1995;155(12):1305-1311.
24. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE Study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75-100.
25. Panda S, Kumar MS, Lokabiraman S, et al. Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr. 2005;39(1):9-15.
26. Kumar MS, Mudaliar S, Thyagarajan SP, et al. Rapid assessment and response to injecting drug use in Madras, south India. Int J Drug Policy. 2000;11(1-2):83-98.
27. Mehta SH, Srikrishnan AK, Celentano DD. The intersection between sex and drugs: HIV prevalence among sexual partners of IDUs in Chennai, India [abstract]. (Abstract W-157). Presented at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 16-19, 2010.
28. Samuels JF, Vlahov D, Anthony JC, et al. Measurement of HIV risk behaviors among intravenous drug users. Br J Addict. 1992;87(3):417-428.
29. Mehta SH, Galai N, Astemborski J, et al. HIV incidence among injection drug users in Baltimore, Maryland (1988- 2004). J Acquir Immune Defic Syndr. 2006;43(3):368-372.
30. Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public health. 2005;95(8): 1439-1444.
31. Kral AH, Lorvick J, Gee L, et al. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol. 2003;157(10):915-922.
32. Steinbrook R. HIV in India-a complex epidemic. N Engl J Med. 2007;356(11):1089-1093.
33. Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet. 2000;356(9224):103-112.
34. Solomon SS, Solomon S, Masse BR, et al. Risk reduction counseling is associated with decreased HIV transmission-associated behaviors in high-risk Indian heterosexuals. J Acquir Immune Defic Syndr. 2006;42(4):478-483.
35. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463-472.
36. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34(5):730-739.